drugset
drugset / Trial / NCT00656539

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

NCT00656539 ↗

Phase 4 Completed 20 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.

Timeline

Start
2008-04
Primary completion
2008-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule — Other

Indications

blepharitis